Repatha Special Precautions

Hepatic impairment: In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on LDL-C reduction. Therefore, close monitoring may be warranted in these patients.
Patients with severe hepatic impairment (Child-Pugh class C) have not been studied (see Pharmacology: Pharmacokinetics under Actions). Evolocumab (Repatha) should be used with caution in patients with severe hepatic impairment.
Dry natural rubber: Evolocumab (Repatha) solution for injection in pre-filled syringe 140 mg: The needle cover of the glass pre-filled syringe is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.
Evolocumab (Repatha) solution for injection in pre-filled autoinjector 140 mg: The needle cover of the pre-filled autoinjector is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.
Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
Effects on ability to drive and use machines: Evolocumab (Repatha) has no or negligible influence on the ability to drive and use machines.